Arrowhead Pharmaceuticals, Inc. Common Stock ARWR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:53:09.390Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:52:58.635844821Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:45:18.587080+00:00
Arrowhead Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 54.83 | 80.8% | 13.7% | 42.08 | 126.7% | 16.3% |
| 25Δ | 53.60 | 78.6% | 11.6% | |||
| 30Δ | 52.42 | 76.7% | 9.6% | 45.74 | 92.8% | 9.4% |
| 35Δ | 51.62 | 78.2% | 8.6% | 46.64 | 95.0% | 8.3% |
| 40Δ | 50.83 | 79.6% | 7.6% | 47.54 | 96.7% | 7.3% |
| 45Δ | 50.04 | 81.1% | 6.6% | 48.28 | 88.2% | 6.1% |
| 50Δ | 49.25 | 81.4% | 5.7% | 49.03 | 79.7% | 4.8% |
| 55Δ | 48.46 | 81.7% | 4.9% | 49.78 | 71.2% | 3.5% |
| 60Δ | 47.67 | 81.9% | 4.1% | 50.78 | 74.4% | 3.0% |
| 65Δ | 46.80 | 83.1% | 3.4% | 51.89 | 82.3% | 2.7% |
| 70Δ | 45.90 | 84.7% | 2.8% | 53.11 | 88.4% | 2.4% |
| 75Δ | 45.00 | 86.2% | 2.3% | 54.49 | 92.2% | 1.9% |
| 80Δ | 43.79 | 88.3% | 1.8% | 56.15 | 95.7% | 1.5% |
20Δ
- Pseudo strike
- 54.83
- IV
- 80.8%
- B/E move
- 13.7%
- Pseudo strike
- 42.08
- IV
- 126.7%
- B/E move
- 16.3%
25Δ
- Pseudo strike
- 53.60
- IV
- 78.6%
- B/E move
- 11.6%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 52.42
- IV
- 76.7%
- B/E move
- 9.6%
- Pseudo strike
- 45.74
- IV
- 92.8%
- B/E move
- 9.4%
35Δ
- Pseudo strike
- 51.62
- IV
- 78.2%
- B/E move
- 8.6%
- Pseudo strike
- 46.64
- IV
- 95.0%
- B/E move
- 8.3%
40Δ
- Pseudo strike
- 50.83
- IV
- 79.6%
- B/E move
- 7.6%
- Pseudo strike
- 47.54
- IV
- 96.7%
- B/E move
- 7.3%
45Δ
- Pseudo strike
- 50.04
- IV
- 81.1%
- B/E move
- 6.6%
- Pseudo strike
- 48.28
- IV
- 88.2%
- B/E move
- 6.1%
50Δ
- Pseudo strike
- 49.25
- IV
- 81.4%
- B/E move
- 5.7%
- Pseudo strike
- 49.03
- IV
- 79.7%
- B/E move
- 4.8%
55Δ
- Pseudo strike
- 48.46
- IV
- 81.7%
- B/E move
- 4.9%
- Pseudo strike
- 49.78
- IV
- 71.2%
- B/E move
- 3.5%
60Δ
- Pseudo strike
- 47.67
- IV
- 81.9%
- B/E move
- 4.1%
- Pseudo strike
- 50.78
- IV
- 74.4%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 46.80
- IV
- 83.1%
- B/E move
- 3.4%
- Pseudo strike
- 51.89
- IV
- 82.3%
- B/E move
- 2.7%
70Δ
- Pseudo strike
- 45.90
- IV
- 84.7%
- B/E move
- 2.8%
- Pseudo strike
- 53.11
- IV
- 88.4%
- B/E move
- 2.4%
75Δ
- Pseudo strike
- 45.00
- IV
- 86.2%
- B/E move
- 2.3%
- Pseudo strike
- 54.49
- IV
- 92.2%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- 43.79
- IV
- 88.3%
- B/E move
- 1.8%
- Pseudo strike
- 56.15
- IV
- 95.7%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 53.16% | |
| 54.90% | |
| 53.49% | |
| 55.24% | |
| 52.73% | |
| 54.10% | |
| 55.61% | |
| 56.39% | |
| 54.89% | |
| 53.90% |
Biotechnology
ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered…
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →